Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib 2020-01-24 14:26
CStone successfully hosted the first U.S. R&D Day in New York 2020-01-24 08:18
CStone successfully hosted the first U.S. R&D Day in New York 2020-01-24 08:03
CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma 2020-01-08 13:45
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia 2019-12-12 14:47
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST 2019-12-11 11:00
CStone's anti-PD-L1 antibody demonstrates promising antitumor activity with a complete response rate of 33.3% and a good safety profile in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma 2019-12-10 11:38
CStone appoints seasoned pharmaceutical executive Shirley Zhao as the General Manager for Greater China and Head of Commercial 2019-12-06 18:53
CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib 2019-11-20 11:41
ASH 2019 | CStone's anti-PD-L1 antibody demonstrates a complete response rate of 31.8% in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma 2019-11-07 11:02
ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability 2019-09-30 18:29
2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors 2019-09-22 14:22
2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab 2019-09-22 13:39
2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors 2019-09-21 00:26
2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8% 2019-09-19 23:48
CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST 2019-08-26 11:21
CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting 2019-08-23 11:26
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study 2019-08-23 11:20
CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting 2019-08-20 10:18
Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress 2019-08-19 13:50
1 2 3 4 5 6